Sight Sciences (SGHT) Projected to Post Quarterly Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is expected to be posting its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Sight Sciences to post earnings of ($0.17) per share and revenue of $20.3540 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

Sight Sciences Price Performance

SGHT opened at $5.25 on Wednesday. Sight Sciences has a 1 year low of $2.03 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93. The company has a market capitalization of $277.57 million, a price-to-earnings ratio of -5.83 and a beta of 2.41. The firm’s fifty day moving average price is $6.77 and its two-hundred day moving average price is $5.73.

Insider Buying and Selling at Sight Sciences

In other Sight Sciences news, CFO James Rodberg sold 4,405 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $7.82, for a total transaction of $34,447.10. Following the completion of the transaction, the chief financial officer owned 154,440 shares in the company, valued at $1,207,720.80. This trade represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jeremy B. Hayden sold 6,308 shares of Sight Sciences stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $6.62, for a total transaction of $41,758.96. Following the completion of the transaction, the insider owned 267,611 shares of the company’s stock, valued at $1,771,584.82. The trade was a 2.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 99,796 shares of company stock valued at $719,722 in the last three months. 28.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sight Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in shares of Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after acquiring an additional 3,785 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares in the last quarter. XTX Topco Ltd bought a new position in Sight Sciences in the 2nd quarter worth about $67,000. O Shaughnessy Asset Management LLC purchased a new position in Sight Sciences during the 4th quarter valued at about $81,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Sight Sciences during the 4th quarter valued at about $96,000. Institutional investors own 55.51% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on SGHT. Citigroup boosted their price target on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a report on Thursday, December 11th. UBS Group lifted their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Morgan Stanley upped their target price on Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Finally, Piper Sandler set a $9.00 price target on Sight Sciences in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.30.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.